Close Menu

NEW YORK (GenomeWeb) – Intrexon today said that it completed a public offering that raised $230 million in gross proceeds. 

The firm sold 5,609,756 shares of its common stock at $41 per share, which included 731,707 shares purchased by the offering's underwriters under an option granted to them by Intrexon. 

JMP Securities was the sole book-running manager while Stifel was the lead manager on the offering. Griffin Securities and Wunderlich Securities were the co-managers. 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Los Angeles brought and settled a civil enforcement action against the makers of an at-home test for SARS-CoV-2, NPR reports. 

The Guardian reports that Cancer Research UK is cutting its research funding by £44 million.

Technology Review examines factors affecting SARS-CoV-2 testing turnaround times.

In PNAS this week: mapping of ancient human migrations in Europe, recurrent gene fusion in breast cancer, and more.